Physician profile

Maritza Archbold

Pediatrics · Bronx, NY

NPI 1427120559

$812.30

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$286.22

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $435.09 2019-2024 Bexsero, Rotarix, Pediarix
Merck Sharp & Dohme LLC $135.41 2019-2023 M-M-R II, Gardasil 9, Vaxelis
Sanofi Pasteur INC. $103.98 2019-2023
Abbott Laboratories $59.93 2022
Pfizer INC. $25.03 2023
Seqirus USA INC $19.96 2023 Flucelvax Quadrivalent
Phadia US INC. $19.09 2020
Cranial Technologies, INC $13.81 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Maritza Archbold

$812.30

in general payments reported 2019-2025

Years
2019-2024
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/1229520/maritza-archbold

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.